Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults

March 14, 2024 updated by: Emergent BioSolutions

A Parallel-arm, Double-blind, Randomized, Placebo-controlled, Dose-ranging Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of AV7909 in Healthy Adults

The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and female subjects between 18 and 50 years of age will receive vaccinations via the intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant medications, and local and systemic signs and symptoms of reactogenicity.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

AV7909 is a new vaccine which is a combination of BioThrax (also called anthrax vaccine, adsorbed or AVA), a FDA-licensed vaccine, and CPG 7909. CPG 7909 is a synthetic short DNA sequence that has been shown to be an effective vaccine adjuvant, and one which increases the speed and the degree of the immune response to Protective Antigen (PA), the major vaccine antigen. In the current study, the safety, tolerability, and antibody response to PA will be studied for four different combinations of AVA and CPG 7909, and compared to both AVA and a saline placebo. All formulations of AV7909 have the same or less AVA than the licensed AVA vaccine and all have less CPG 7909 per dose than the formulation used in the first Phase I volunteer study of CPG 7909 combined with AVA.

Study Type

Interventional

Enrollment (Actual)

105

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Florida
      • Miami, Florida, United States, 33143
        • Miami Research Associates
    • North Carolina
      • Raleigh, North Carolina, United States, 27607
        • North Carolina Clinical Research
    • Utah
      • Salt Lake City, Utah, United States, 84124
        • Jean Brown Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Be between 18 and 50 years of age, inclusive, at the time of enrollment.
  • Be in good health as determined by the investigator from medical history and a physical examination.
  • If a pre-menopausal female, must be using acceptable methods of birth control.
  • Have all hematology and chemistry parameters (measured at Screening) within the laboratory's normal range.
  • Have negative values for the following tests at Screening: Hepatitis C antibody, anti-Human Immunodeficiency Virus (Anti-HIV-1/-2/-O), and anti-Hepatitis B Core Antigen (Anti-HBc).
  • Be willing and capable of complying with all aspects of the protocol through completion of the required visits.
  • Have not donated blood in the preceding 8 weeks and are willing to not donate blood or plasma within 56 days after dosing.
  • Have adequate venous access for repeat phlebotomies.
  • Have read, understood and signed an informed consent form.

Exclusion Criteria:

Key Exclusion Criteria:

  • A known anaphylactic response, severe systematic response, or serious hypersensitivity reaction to a prior immunization.
  • Prior immunization with anthrax vaccine, recombinant Protective Antigen (rPA) vaccine, or known exposure to anthrax organisms.
  • Have previously served in the military or plans to enlist in the military from Screening through Day 84.
  • Have participated in anthrax therapeutic or vaccine trials (monoclonal anti-protective antigen (PA) or anthrax immune globulins or anthrax vaccines).
  • Participation in any investigational clinical trial within 30 days preceding the Screening visit or planning to participate in a clinical trial requiring dosing through the Day 194 visit.
  • A history of drug or alcohol abuse within 12 months prior to Screening, or a positive result on a urine drug screen for amphetamines, barbiturates, benzodiazepines, cocaine, marijuana, methylenedioxymethamphetamine opiates, oxycodone, phencyclidine, propoxyphene, or tricyclic antidepressants.
  • Blood pressure greater than 145 millimeters of mercury (mmHg) systolic or 90 mmHg diastolic.
  • Past history of significant autoimmune disease such as rheumatoid arthritis, lupus erythematous, psoriasis, glomerulonephritis, or autoimmune thyroiditis.
  • A medical condition that, in the opinion of the Principal Investigator (PI), could adversely impact the subject's participation, safety, or conduct of the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: BioThrax
BioThrax, 0.5 mL AVA per dose
Biological: BioThrax
BioThrax
Other Names:
  • Anthrax Vaccine Adsorbed (AVA)
Experimental: AV7909 Formulation 1
0.5 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
Biological: AV7909 Formulation 1
AV7909 Formulation 1
Experimental: AV7909 Formulation 2
0.5 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
Biological: AV7909 Formulation 2
AV7909 Formulation 2
Experimental: AV7909 Formulation 3
0.25 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
Biological: AV7909 Formulation 3
AV7909 Formulation 3
Experimental: AV7909 Formulation 4
0.25 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
Biological: AV7909 Formulation 4
AV7909 Formulation 4
Placebo Comparator: Control
Saline control
Drug: Control
Saline control

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Vaccination (Day 0)
Time Frame: Days 0-6

Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the first injection (Day 0).

All local reactions collected by subjects on diary cards were recorded as adverse events.

Severity of ISR was assessed using a grading scale based on FDA Guidance "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."

Swelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:

  • Grade 0: none
  • Grade 1: <3 cm
  • Grade 2: 3 to 10 cm
  • Grade 3: >10 cm

For all other ISRs, the following scale was used:

  • Grade 0: not present
  • Grade 1: present with no limitation of activity
  • Grade 2: interfering with daily activities or requiring non-narcotic treatment
  • Grade 3: preventing normal daily activities or requiring narcotic analgesia
Days 0-6
Percentage of Subjects With Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Vaccination (Day 0)
Time Frame: Days 0-6

Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the first injection (Day 0).

All local reactions collected by subjects on diary cards were recorded as adverse events.

Severity of ISR was assessed using a grading scale based on FDA Guidance "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."

Swelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:

  • Grade 0: none
  • Grade 1: <3 cm
  • Grade 2: 3 to 10 cm
  • Grade 3: >10 cm

For all other ISRs, the following scale was used:

  • Grade 0: not present
  • Grade 1: present with no limitation of activity
  • Grade 2: interfering with daily activities or requiring non-narcotic treatment
  • Grade 3: preventing normal daily activities or requiring narcotic analgesia
Days 0-6
Incidence of Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Vaccination (Day 14)
Time Frame: Days 14-20

Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the second injection (Day 14).

All local reactions collected by subjects on diary cards were recorded as adverse events.

Severity of ISR was assessed using a grading scale based on FDA Guidance "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."

Swelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:

  • Grade 0: none
  • Grade 1: <3 cm
  • Grade 2: 3 to 10 cm
  • Grade 3: >10 cm

For all other ISRs, the following scale was used:

  • Grade 0: not present
  • Grade 1: present with no limitation of activity
  • Grade 2: interfering with daily activities or requiring non-narcotic treatment
  • Grade 3: preventing normal daily activities or requiring narcotic analgesia
Days 14-20
Percentage of Subjects With Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Vaccination (Day 14)
Time Frame: Days 14-20

Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the second injection (Day 14).

All local reactions collected by subjects on diary cards were recorded as adverse events.

Severity of ISR was assessed using a grading scale based on FDA Guidance "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."

Swelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:

  • Grade 0: none
  • Grade 1: <3 cm
  • Grade 2: 3 to 10 cm
  • Grade 3: >10 cm

For all other ISRs, the following scale was used:

  • Grade 0: not present
  • Grade 1: present with no limitation of activity
  • Grade 2: interfering with daily activities or requiring non-narcotic treatment
  • Grade 3: preventing normal daily activities or requiring narcotic analgesia
Days 14-20
Incidence of Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Injection (Day 0)
Time Frame: Days 0-6

Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.

Severity of systemic reactions was assessed using a grading scale based on FDA Guidance titled "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."

Toxicity grades for fever were derived from body temperature using the following scale:

  • Grade 0: <100°F
  • Grade 1: 100.0 - 101.5°F
  • Grade 2: 101.6 - 102.9°F ;
  • Grade 3: 103.0 - 105.0°F

For all other systemic reactions, the following scale was used:

  • Grade 0: not present
  • Grade 1: present with no limitation of activity
  • Grade 2: interfering with daily activities or requiring non-narcotic treatment
  • Grade 3: preventing normal daily activities or requiring narcotic analgesia
Days 0-6
Percentage of Subjects With Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Injection (Day 0)
Time Frame: Days 0-6

Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.

Severity of systemic reactions was assessed using a grading scale based on FDA Guidance titled "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."

Toxicity grades for fever were derived from body temperature using the following scale:

  • Grade 0: <100°F
  • Grade 1: 100.0 - 101.5°F
  • Grade 2: 101.6 - 102.9°F ;
  • Grade 3: 103.0 - 105.0°F

For all other systemic reactions, the following scale was used:

  • Grade 0: not present
  • Grade 1: present with no limitation of activity
  • Grade 2: interfering with daily activities or requiring non-narcotic treatment
  • Grade 3: preventing normal daily activities or requiring narcotic analgesia
Days 0-6
Incidence of Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Injection (Day 14)
Time Frame: Days 14-20

Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.

Severity of systemic reactions was assessed using a grading scale based on FDA Guidance titled "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."

Toxicity grades for fever were derived from body temperature using the following scale:

  • Grade 0: <100°F
  • Grade 1: 100.0 - 101.5°F
  • Grade 2: 101.6 - 102.9°F ;
  • Grade 3: 103.0 - 105.0°F

For all other systemic reactions, the following scale was used:

  • Grade 0: not present
  • Grade 1: present with no limitation of activity
  • Grade 2: interfering with daily activities or requiring non-narcotic treatment
  • Grade 3: preventing normal daily activities or requiring narcotic analgesia
Days 14-20
Percentage of Subjects With Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Injection (Day 14)
Time Frame: Days 14-20

Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.

Severity of systemic reactions was assessed using a grading scale based on FDA Guidance titled "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."

Toxicity grades for fever were derived from body temperature using the following scale:

  • Grade 0: <100°F
  • Grade 1: 100.0 - 101.5°F
  • Grade 2: 101.6 - 102.9°F ;
  • Grade 3: 103.0 - 105.0°F

For all other systemic reactions, the following scale was used:

  • Grade 0: not present
  • Grade 1: present with no limitation of activity
  • Grade 2: interfering with daily activities or requiring non-narcotic treatment
  • Grade 3: preventing normal daily activities or requiring narcotic analgesia
Days 14-20
Incidence of Hematology, Serum Chemistry, and Urinalysis Abnormalities Reported as Adverse Events
Time Frame: Days 0-56

Hematology test included hemoglobin, hematocrit, white blood cell count, absolute lymphocyte count, absolute neutrophil count, absolute eosinophil count, and platelet count. Serum chemistry test included albumin, alkaline phosphatase, total bilirubin, blood urea nitrogen, creatinine, glucose, calcium, potassium, alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase. Urinalysis included appearance, color, pH, specific gravity, ketones, protein, glucose, bilirubin, nitrite, urobilinogen, and occult blood.

Hematology tests were done on Days 0, 1, 2, 7, 28, and 56. Serum chemistry tests and urinalysis were done on Days 0, 7, 28, and 56.
Days 0-56
Percentage of Subjects With Hematology, Serum Chemistry, and Urinalysis Abnormalities Reported as Adverse Events
Time Frame: Days 0-56

Hematology test included hemoglobin, hematocrit, white blood cell count, absolute lymphocyte count, absolute neutrophil count, absolute eosinophil count, and platelet count. Serum chemistry test included albumin, alkaline phosphatase, total bilirubin, blood urea nitrogen, creatinine, glucose, calcium, potassium, alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase. Urinalysis included appearance, color, pH, specific gravity, ketones, protein, glucose, bilirubin, nitrite, urobilinogen, and occult blood.

Hematology tests were done on Days 0, 1, 2, 7, 28, and 56. Serum chemistry tests and urinalysis were done on Days 0, 7, 28, and 56.
Days 0-56

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peak TNA NF50 GMT for All Subjects in the Immunogenicity Population and by Gender After IM Administration of Investigational Product on Days 0 and 14.
Time Frame: Day 0 (pre-dose), 7, 14 (pre-dose), 21, 28, 35, 42, 56, 70, and 84.
Toxin neutralizing antibody (TNA) levels in blinded serum samples were measured using a validated anthrax lethal toxin neutralization assay. The primary assay endpoint was the 50% neutralization factor (TNA NF50). TNA NF50 is calculated as the ratio of the 50% effective dose (ED50) of the test sample to the ED50 of a reference serum. Values below the lower limit of quantitation (LLOQ) of the assay (ED50 of 33) were replaced with one-half the LLOQ (ED50 of 16.5) for calculation of geometric mean titer (GMT) and statistical analysis. GMT is based on log transformation.
Day 0 (pre-dose), 7, 14 (pre-dose), 21, 28, 35, 42, 56, 70, and 84.
Median Time to Peak TNA NF50 GMT for All Subjects in the Immunogenicity Population and by Gender After IM Administration of Investigational Product on Days 0 and 14.
Time Frame: Day 0 (pre-dose), 7, 14 (pre-dose), 21, 28, 35, 42, 56, 70, and 84.
Toxin neutralizing antibody (TNA) levels in blinded serum samples were measured using a validated anthrax lethal toxin neutralization assay. The primary assay endpoint was the 50% neutralization factor (TNA NF50). TNA NF50 is calculated as the ratio of the 50% effective dose (ED50) of the test sample to the ED50 of a reference serum. Values below the LLOQ of the assay (ED50 of 33) were replaced with one-half the LLOQ (ED50 of 16.5) for calculation of geometric mean titer (GMT) and statistical analysis. GMT is based on log transformation.
Day 0 (pre-dose), 7, 14 (pre-dose), 21, 28, 35, 42, 56, 70, and 84.
TNA NF50 GMTs Across Study Days After IM Administration of Investigational Product on Days 0 and 14.
Time Frame: Day 0 (pre-dose), 7, 14 (pre-dose), 21, 28, 35, 42, 56, 70, and 84.
Toxin neutralizing antibody (TNA) levels in blinded serum samples were measured using a validated anthrax lethal toxin neutralization assay. The primary assay endpoint was the 50% neutralization factor (TNA NF50). TNA NF50 is calculated as the ratio of the 50% effective dose (ED50) of the test sample to the ED50 of a reference serum. Values below the LLOQ of the assay (ED50 of 33) were replaced with one-half the LLOQ (ED50 of 16.5) for calculation of geometric mean titer (GMT) and statistical analysis. GMT is based on log transformation.
Day 0 (pre-dose), 7, 14 (pre-dose), 21, 28, 35, 42, 56, 70, and 84.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Emergent BioSolutions

Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)
Department of Health and Human Services

Investigators

  • Study Director: Edward Bernton, MD, Emergent Biosolutions, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2010

Primary Completion (Actual)

May 1, 2012

Study Completion (Actual)

June 1, 2012

Study Registration Dates

First Submitted

December 17, 2010

First Submitted That Met QC Criteria

December 20, 2010

First Posted (Estimated)

December 21, 2010

Study Record Updates

Last Update Posted (Actual)

March 18, 2024

Last Update Submitted That Met QC Criteria

March 14, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EBS.AVA.201 / DMID 10-0013
  • HHSN272200800051C (Other Grant/Funding Number: BARDA/NIAID)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bacillus Anthracis (Anthrax) Infection

Clinical Trials on BioThrax

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe